Biotech Insider Buying to Watch: Arrowhead Research Corp. (NASDAQ:ARWR), VIVUS Inc. (NASDAQ:VVUS), CorMedix (NYSEMKT: CRMD), Synageva BioPharma (NASDAQ:GEVA), Ligand Pharmaceuticals (NASDAQ:LGND)

On 12 January Arrowhead Research Corp. (NASDAQ:ARWR) announced that the U.S. Food and Drug Administration (FDA) verbally informed the Company in a preliminary call of a partial clinical hold, under which the Company is cleared to begin a modified multiple-dose study of ARC-520 in patients with chronic hepatitis B infection. On Wednesday shares of Arrowhead Research Corp. (NASDAQ:ARWR) closed at $6.71. Company’s sales growth for last 5 years was -44.50% and EPS growth for next 5 years is recorded as 7.33%.

VIVUS Inc. (NASDAQ:VVUS) major shareholder North Tide Capital, Llc acquired 500,000 shares of the stock in a transaction dated Thursday, January 8th. The shares were purchased at an average price of $3.12 per share, with a total value of $1,560,000.00. VIVUS Inc. (NASDAQ:VVUS) in last trading activity fell -2.91% to close at $3.00. Company weekly performance is -4.15% while its quarterly performance stands at -11.24%. VIVUS Inc. (NASDAQ:VVUS) is -69.39% away from its 52 week high.

Roth Capital set a $2.50 price objective on CorMedix, Inc. (NYSEMKT: CRMD) in a report released on Wednesday. The firm currently has a buy rating on the stock On last trading day CorMedix, Inc. (NYSEMKT: CRMD) increased 14.57% to close at $2.28. Its volatility for the week is 10.34% while volatility for the month is 8.74%. CRMD’s EPS growth for past 5 years was 4.10%. CorMedix, Inc. (NYSEMKT: CRMD) monthly performance is 64.03%.

Synageva Biopharma Corp (NASDAQ:GEVA) Director Julian Baker purchased 1,000,000 shares of the company’s stock in a transaction that occurred on Wednesday, January 7th. The stock was purchased at an average price of $94.19 per share, for a total transaction of $94,190,000.00. Following the completion of the acquisition, the director now directly owns 1,020 shares of the company’s stock, valued at approximately $96,073.80. Synageva BioPharma Corp. (NASDAQ:GEVA) has 0.20% insider ownership while its institutional ownership stands at 66.00%. In last trading activity company’s stock closed at $111.17.

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) VP, Gen. Counsel & Secretary Berkman Charles S had purchased shares worth of $5,699 in a transaction dated on December 31, 2014. On last trading day Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) increased 0.83% to close at $52.47. Its volatility for the week is 4.42% while volatility for the month is 4.09%. LGND’s sales growth for past 5 years was 12.40% and its EPS growth for past 5 years was 15.70%. Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) monthly performance is -0.10%.

Leave a Reply

Your email address will not be published. Required fields are marked *